Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
April 11, 2025
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
May 12, 2025 Non RegulatorySynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy
-
May 8, 2025 Non RegulatorySynAct to host Capital Markets Day in Stockholm June 4
-
April 24, 2025 RegulatoryNotice of annual general meeting in SynAct Pharma AB
A MESSAGE FROM OUR CEO
”Ensuring the RA trial stays on track is key, but there are other diseases where activating the melanokortin system can potentially make a big impact.”